Bimatoprost

證據等級: L5

預測適應症: 10 個

Bimatoprost: From Glaucoma / Eyelash Hypotrichosis to Alopecia

One-Sentence Summary

Bimatoprost (Lumigan / Latisse) is a synthetic prostamide F2α analogue originally approved for treating ocular hypertension and open-angle glaucoma, with a secondary FDA approval for eyelash hypotrichosis arising from an observed side effect in glaucoma patients. The TxGNN model predicts it may be effective for Alopecia (hair loss) — an anatomically adjacent extension of its already-approved eyelash indication — with 11 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Ocular hypertension / Open-angle glaucoma; Eyelash hypotrichosis (FDA-approved Latisse)
Predicted New Indication	Alopecia (hair loss, including androgenetic alopecia and alopecia areata)
TxGNN Prediction Score	99.99%
Evidence Level	L2
Singapore Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Bimatoprost acts as a synthetic prostamide F2α analogue with high affinity for the FP (prostaglandin F) receptor. In the eye, FP receptor activation reduces aqueous humour production and lowers intraocular pressure — the mechanism underlying its use in glaucoma. An unexpected but consistent finding in glaucoma patients receiving bimatoprost eyedrops was increased eyelash length, thickness, and pigmentation. This observation was systematically studied and led to the FDA approval of Latisse (bimatoprost 0.03%) for eyelash hypotrichosis — the first and only FDA-approved treatment for this indication.

The connection to scalp alopecia is mechanistically direct. Hair follicles throughout the body share the same FP receptor pathway. Bimatoprost promotes the transition of follicles from telogen (resting) into anagen (active growth) phase and extends the duration of anagen. This is precisely the mechanism disrupted in androgenetic alopecia (AGA), where DHT progressively shortens anagen and miniaturises follicles, and in alopecia areata, where immune-mediated attack disrupts the hair cycle. The FP-receptor route operates independently of the androgen pathway, making bimatoprost a potentially complementary or alternative option to finasteride and minoxidil.

Critically, this is not merely theoretical. Three large completed Phase 2 trials — two with over 300 participants each, covering both male AGA and female pattern hair loss — directly tested topical bimatoprost on the scalp. The mechanistic leap from eyelash to scalp represents an anatomical extension rather than a fundamentally new biological question, which is why TxGNN assigns a near-perfect score and why the clinical evidence base has grown significantly over the past decade.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01325337	Phase 2	Completed	307	Three doses of bimatoprost solution vs vehicle and open-label minoxidil 5% in male AGA; the largest and most pivotal bimatoprost scalp efficacy trial
NCT01325350	Phase 2	Completed	306	Mirror design to NCT01325337 in women with female pattern hair loss (FPHL); bimatoprost vs vehicle and minoxidil 2% — together these two trials provide the broadest gender coverage
NCT01904721	Phase 2	Completed	244	Safety and efficacy of bimatoprost in male AGA; a second core Phase 2 efficacy dataset confirming the dose-response relationship
NCT05600673	Phase 1/2	Completed	30	CO2 fractional laser combined with bimatoprost 0.03% in alopecia areata; evaluated whether bimatoprost augments hair regrowth following laser-induced immune disruption
NCT02170662	Phase 2	Completed	33	Mechanistic investigation of bimatoprost on androgen-dependent scalp follicles; provided biological marker data supporting FP-receptor-mediated anagen promotion
NCT00187577	N/A	Completed	14	Randomised comparison of latanoprost vs bimatoprost ophthalmic solution for eyelash regrowth in alopecia areata; early proof-of-concept for PGF2α analogues in AA
NCT01023841	Phase 4	Completed	71	Post-marketing safety and efficacy of bimatoprost 0.03% for eyelash hypotrichosis in children; confirms paediatric tolerability of the core eyelash indication
NCT02848300	Phase 1	Completed	11	Scalp pharmacokinetics and tolerability of two bimatoprost formulations over 14 days in male AGA; characterised dermal absorption profile
NCT01189279	Phase 1	Completed	42	Safety, tolerability, and PK of a new bimatoprost topical formulation in alopecia patients; supported formulation development for scalp delivery
NCT02676310	Phase 1	Terminated	53	Dose-escalation safety and PK study in male AGA; terminated early without completing full efficacy data collection

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40252129	2025	RCT / Clinical Study	Archives of Dermatological Research	CO2 fractional laser + bimatoprost significantly enhanced hair regrowth in alopecia areata compared with laser alone; supports bimatoprost as an adjunct in AA
32250713	2022	Systematic Review	J Dermatological Treatment	Network meta-analysis of all non-surgical AGA treatments in men and women; bimatoprost included and compared against minoxidil, finasteride, and other agents
37089845	2023	Prospective Non-Randomised	Indian Dermatology Online Journal	Bimatoprost vs clobetasol propionate in scalp alopecia areata; bimatoprost showed comparable hair regrowth with a favourable safety profile
35278027	2022	Prospective Cohort	Dermatologic Therapy	Prospective study of bimatoprost ophthalmic solution for eyelash loss in alopecia totalis and universalis; 16/19 evaluable patients showed clinically meaningful regrowth
28264599	2017	Review	Expert Opinion on Investigational Drugs	Comprehensive review of bimatoprost for eyelash, eyebrow, and scalp alopecia; covers mechanism, clinical evidence, and positioning relative to standard of care
23104985	2013	Mechanistic / Case Series	FASEB Journal	Foundational paper proposing prostamide-related therapy for scalp alopecias; demonstrated bimatoprost effects on human scalp follicles ex vivo
29854658	2018	Review	Indian Dermatology Online Journal	Overview of bimatoprost in dermatology; documents the pathway from glaucoma side effects to purposeful use in eyelashes, scalp alopecia, and vitiligo
37185388	2023	Review	Current Oncology	Prevention and treatment of chemotherapy-induced alopecia; bimatoprost noted as an emerging topical option for CIA
29863806	2018	Clinical Guideline	Journal of Dermatology	Japanese 2017 guidelines for male/female pattern hair loss; includes review of emerging therapies including PGF2α analogues
27377163	2016	Case Report	Pediatric Dermatology	Steroid-resistant multifocal scalp AA in a child successfully treated with topical bimatoprost; supports off-label use in paediatric refractory AA

Singapore Market Information

Bimatoprost is currently not registered with HSA Singapore. No product licences were identified as of the data cutoff (2026-06-01).

For reference, bimatoprost is available internationally under the following brand names:

Brand Name	Indication	Regulatory Status
Lumigan (Allergan/AbbVie)	Glaucoma / Ocular hypertension	FDA-approved (USA); approved in EU, Japan, and many other markets
Latisse (Allergan/AbbVie)	Eyelash hypotrichosis	FDA-approved (USA, 2008)

Registration in Singapore via HSA would be required before any local clinical use.

Safety Considerations

Detailed local safety data (HSA-registered package insert warnings and contraindications) are not available for Singapore as the drug is not registered. Based on the internationally approved prescribing information, the following are known considerations:

Known ocular side effects (ophthalmic use): Conjunctival hyperaemia, gradual iris pigmentation change (irreversible), periorbital fat atrophy, and eyelid ptosis with prolonged periocular application
Respiratory caution: Systemic prostaglandin activity may trigger bronchospasm; use with caution in patients with asthma or COPD
Pigmentation effects: Increased skin and hair pigmentation at application sites reported; relevant for scalp applications

Please refer to the full Lumigan and Latisse prescribing information for complete safety details before clinical use.

Appendix: Other TxGNN-Predicted Indications

The TxGNN model returned 10 predictions for bimatoprost. The table below summarises all ranked predictions with their evidence status:

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation	Notes
1	Malformation syndrome with periodontal component	99.997%	L5	Hold	No bimatoprost-specific evidence; 20 general periodontal papers; likely graph false positive via indirect prostaglandin–periodontium nodes
2	Syndrome with Dandy-Walker malformation	99.997%	L5	Hold	Congenital posterior fossa malformation; no known FP-receptor connection; 0 trials, 0 papers
3	Isolated genetic hair shaft abnormality	99.997%	L5	Hold	Structural keratin/desmoplakin gene defect; bimatoprost cannot correct protein structure; 0 evidence
4	Ambras-type hypertrichosis universalis congenita	99.997%	L5	Hold	Congenital excessive hair growth — bimatoprost would worsen the condition; mechanistically contraindicated
5	Hypotrichosis simplex of the scalp	99.996%	L3	Research Question	Mechanistically plausible extension of Latisse indication to scalp; no dedicated trials yet
6	Congenital hypotrichosis with milia	99.995%	L5	Hold	Genetic skin appendage developmental defect; unclear whether growth-phase promotion can overcome developmental gene defects
7	Diffuse alopecia areata	99.993%	L3	Research Question	Plausible via FP-receptor anagen promotion; trials on patchy AA exist (NCT05600673) but diffuse subtype needs specific validation
8	Alopecia	99.993%	L2	Proceed with Guardrails	Best-evidenced prediction; 11 clinical trials including 3 Phase 2 trials (n > 250 each); see main report above
9	Genetic alopecia	99.966%	L3	Research Question	Androgenetic alopecia is polygenic; bimatoprost provides a non-androgenic (FP receptor) complementary pathway
10	Pulmonary arteriovenous malformation	99.955%	L5	Hold	Vascular structural anomaly (HHT/ALK1 pathway); no overlap with FP receptor signalling; graph false positive

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Three completed Phase 2 trials enrolling over 850 participants collectively have evaluated topical bimatoprost in androgenetic alopecia and female pattern hair loss. The mechanism — FP receptor-mediated anagen promotion — is a direct, anatomically adjacent extension of Latisse's FDA-approved eyelash indication, making this the most scientifically credible repurposing candidate in the dataset. However, Phase 2 results for scalp AGA have shown mixed primary endpoint outcomes, and no Phase 3 trial has been completed for scalp indications.

To proceed, the following is needed:

Regulatory pathway: Register bimatoprost with HSA Singapore; no local approval currently exists
Formulation development: Standard 0.03% ophthalmic solution has suboptimal scalp bioavailability; enhanced permeation formulations (e.g., spanlastics, co-solvent systems) are under preclinical investigation and should be prioritised
Target population definition: Clearly delineate between AGA (androgenetic alopecia), alopecia areata subtypes (patchy, diffuse, totalis/universalis), and chemotherapy-induced alopecia — each may require different dosing and endpoints
Phase 3 evidence: No Phase 3 trial for scalp AGA has been completed; this is the key evidence gap before regulatory submission for a new indication
Safety data package: Obtain full HSA-relevant safety dossier including DDI data, contraindications, and local labelling requirements
Mechanistic action data (MOA): Formal DrugBank/SmPC documentation of the FP-receptor mechanism should be retrieved to support any regulatory submission
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.